2024 ICD-10-CM Diagnosis Code E85.2

Heredofamilial amyloidosis, unspecified

ICD-10-CM Code:
ICD-10 Code for:
Heredofamilial amyloidosis, unspecified
Is Billable?
Yes - Valid for Submission
Chronic Condition Indicator: [1]
Code Navigator:

Code Classification

  • Endocrine, nutritional and metabolic diseases

E85.2 is a billable diagnosis code used to specify a medical diagnosis of heredofamilial amyloidosis, unspecified. The code is valid during the current fiscal year for the submission of HIPAA-covered transactions from October 01, 2023 through September 30, 2024.

Unspecified diagnosis codes like E85.2 are acceptable when clinical information is unknown or not available about a particular condition. Although a more specific code is preferable, unspecified codes should be used when such codes most accurately reflect what is known about a patient's condition. Specific diagnosis codes should not be used if not supported by the patient's medical record.

Approximate Synonyms

The following clinical terms are approximate synonyms or lay terms that might be used to identify the correct diagnosis code:

  • ABri amyloidosis
  • ADan amyloidosis
  • AGel amyloidosis
  • Amyloid myopathy
  • Amyloid nephropathy
  • Amyloid nephropathy
  • Autosomal dominant beta2-microglobulinic amyloidosis
  • Cerebral amyloid angiopathy
  • Cerebral amyloid angiopathy
  • Cerebral amyloid angiopathy
  • Cerebral amyloid angiopathy
  • Cryopyrin associated periodic syndrome
  • Familial amyloid nephropathy with urticaria AND deafness
  • Familial lichen amyloidosis
  • Familial localized cutaneous amyloidosis
  • Familial non-neuropathic amyloidosis
  • Familial visceral amyloidosis, Ostertag type
  • Hereditary amyloidosis
  • Hereditary cerebrovascular amyloidosis
  • Hereditary systemic amyloidosis
  • Heredofamilial systemic amyloidosis affecting skin
  • ITM2B-related amyloidosis
  • Localized hereditary amyloidosis
  • Localized hereditary amyloidosis
  • Localized hereditary cardiac amyloidosis
  • Primary familial amyloid myopathy
  • Primary localized cutaneous amyloidosis
  • Prion protein systemic amyloidosis
  • Systemic amyloidosis affecting skin
  • Systemic amyloidosis affecting skin

Clinical Classification

Clinical Information

  • Amyloid Neuropathies, Familial

    inherited disorders of the peripheral nervous system associated with the deposition of amyloid in nerve tissue. the different clinical types based on symptoms correspond to the presence of a variety of mutations in several different proteins including transthyretin (prealbumin); apolipoprotein a-i; and gelsolin.
  • Cerebral Amyloid Angiopathy

    a heterogeneous group of sporadic or familial disorders characterized by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges. clinical features include multiple, small lobar cerebral hemorrhage; cerebral ischemia (brain ischemia); and cerebral infarction. cerebral amyloid angiopathy is unrelated to generalized amyloidosis. amyloidogenic peptides in this condition are nearly always the same ones found in alzheimer disease. (from kumar: robbins and cotran: pathologic basis of disease, 7th ed., 2005)
  • Cerebral Amyloid Angiopathy, Familial

    a familial disorder marked by amyloid deposits in the walls of small and medium sized blood vessels of cerebral cortex and meninges.
  • Cerebral Amyloid Angiopathy

    a disorder characterized by the deposition of amyloid in the wall of the vessels in the brain.
  • Cerebral Amyloid Angiopathy, APP-Related|HCHWAD|Hereditary Cerebral Hemorrhage with Amyloidosis-Dutch Type

    an autosomal dominant form of cerebral amyloid angiopathy caused by mutation(s) in the app gene, encoding amyloid-beta a4 protein. the deposition of amyloid in cerebral blood vessels wall may lead to degenerative vascular changes that may result in cerebral hemorrhage. mutation(s) in the app gene may also cause autosomal dominant alzheimer disease 1.

Index to Diseases and Injuries References

The following annotation back-references for this diagnosis code are found in the injuries and diseases index. The Index to Diseases and Injuries is an alphabetical listing of medical terms, with each term mapped to one or more ICD-10-CM code(s).

Convert E85.2 to ICD-9-CM

  • ICD-9-CM Code: 277.39 - Amyloidosis NEC
    Approximate Flag - The approximate mapping means there is not an exact match between the ICD-10 and ICD-9 codes and the mapped code is not a precise representation of the original code.

Patient Education


Amyloidosis occurs when abnormal proteins called amyloids build up and form deposits. The deposits can collect in organs such as the kidney and heart. This can cause the organs to become stiff and unable to work the way they should.

There are three main types of amyloidosis:

  • Primary - with no known cause
  • Secondary - caused by another disease, including some types of cancer
  • Familial - passed down through genes

Symptoms can vary, depending upon which organs are affected. Treatment depends on the type of amyloidosis you have. The goal is to help with symptoms and limit the production of proteins. If another disease is the cause, it needs to be treated.

[Learn More in MedlinePlus]

Code History

  • FY 2024 - No Change, effective from 10/1/2023 through 9/30/2024
  • FY 2023 - No Change, effective from 10/1/2022 through 9/30/2023
  • FY 2022 - No Change, effective from 10/1/2021 through 9/30/2022
  • FY 2021 - No Change, effective from 10/1/2020 through 9/30/2021
  • FY 2020 - No Change, effective from 10/1/2019 through 9/30/2020
  • FY 2019 - No Change, effective from 10/1/2018 through 9/30/2019
  • FY 2018 - No Change, effective from 10/1/2017 through 9/30/2018
  • FY 2017 - No Change, effective from 10/1/2016 through 9/30/2017
  • FY 2016 - New Code, effective from 10/1/2015 through 9/30/2016. This was the first year ICD-10-CM was implemented into the HIPAA code set.


[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:

  • The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
  • The condition places limitations on self-care, independent living, and social interactions.